Although such assumptions are valid for some recurrent mutations such as the L858R mutation in epidermal growth factor receptor (EGFR) in lung cancer [11] and V600E in BRAF in melanoma [12], [13], there is emerging evidence that rare mutations can be drivers [7], [14]–[16]. This evidence concerns the gene EGFR and lung cancer.